Data from clinical trials seem to suggest that MET-protein overexpression is less effective as a predictive biomarker in NSCLC than amplification or mutations of the MET gene, which could be explained not only by expression heterogeneity in tumor tissue and sample types, but also by the differences in IHC platforms, commercially available antibodies, and cutoffs for immunohistochemical positivity used in these clinical studies [4,5]. The gene discussed is MET; the disease is neoplasm.